1	Immunogenicity, Safety and Effectiveness of COVID-19 Pfizer-BioNTech
2	(BNT162b2) mRNA Vaccination in Immunocompromised Adolescents and
3	Young Adults: A systematic Review and Meta-Analyses
4	
5	Patrick DMC Katoto <sup>1,2,3</sup> , Mireille AM Kakubu <sup>4</sup> , Jacques L. Tamuzi <sup>2</sup> , Amanda S. Brand <sup>2</sup> ,
6	Adaeze Ayuk <sup>5</sup> , Liliane N. Byamungu <sup>6</sup> , Charles S. Wiysonge <sup>2,7,8</sup> , Glenda Gray <sup>1</sup>
7	
8	<sup>1</sup> Office of the President and CEO, South African Medical Research Council, Cape Town, South Africa
9	<sup>2</sup> Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of
10	Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South
11	Africa
12	<sup>3</sup> Centre for Tropical Diseases and Global Health, Department of Medicine, Catholic University of
13	Bukavu, DR Congo
14	<sup>4</sup> Ministry of Health and Social Services of Namibia, Windhoek, Namibia.
15	<sup>5</sup> Department of Paediatrics and Child Health, University of Nigeria Teaching Hospital, Enugu, Nigeria
16	<sup>6</sup> Department of Paediatric, Faculty of Medicine and Health Sciences, University of KwaZulu-Natal,
17	Durban, South Africa
18	<sup>7</sup> Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
19	<sup>8</sup> HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban,
20	South Africa
21	
22	
23	<u>Corresponding author</u> :
24	Associate Professor Patrick DMC KATOTO, MD, MSC, PhD
25	Office of the President and CEO, South African Medical Research Council,
26	Francie van Zijl Drive, Parow Valley, Cape Town 7501, South Africa
27	Email: katoto@sun.ac.za, Tel: +27 21 9380340
28	
29	

#### 30 Abstract

People with weak immune systems are more likely to develop severe COVID-19, less likely to 31 32 be included in vaccine controlled studies but more likely to be under-vaccinated. We review 33 post-marketing studies to examine the immunogenicity, safety and effectiveness of BNT162b2 34 vaccine in immunocompromised adolescents and young adults (AYA). We searched more than 35 three international databases from 2020 to 30 May 2022 and used the ROBINS-I for bias 36 assessment. Random effect model was used to estimate pooled proportion, log RR, and mean 37 difference. Egger's regression and Begg's rank correlation were used to examine publication 38 bias. 47 full texts were reviewed, and nine were included. Conditions studied were rheumatic 39 diseases, diabetes mellitus, Down syndrome, solid tumours, neurodisability, and cystic fibrosis. 40 Eight studies used cohort designs and one used cross-sectional designs. Europe led most of the 41 investigations. Most studies had unclear risk of bias and none could rule out selection bias, 42 ascertainment bias, or selective outcome reporting. The overall estimated proportion of 43 combined local and systemic reactions after the first BNT162b2 vaccination was 30%[95% CI: 44 17-42%] and slightly rose to 32% [95% CI: 19-44%] after the second dose. Rheumatic illnesses 45 had the highest rate of AEFI (40%[95% CI: 16-65%]), while cystic fibrosis had the lowest 46 (27%[95% CI: 17%-38%]). Hospitalizations for AEFIs were rare. Healthy controls exhibited 47 higher levels of neutralizing antibodies and measured IgG than immunocompromised AYA, 48 although pooled estimations did not demonstrate a statistically significant difference after 49 primary dose. BNT162b2 is safe and effective in immunocompromised AYA, with no 50 significant difference to healthy controls. However, current evidence is low to moderate due to 51 high RoB. Our research advocates for improving methodology in studies including specific 52 AYA population.

53

Key words: SARS-CoV-2, Children, comorbidity, Immunisation, post marketing 54

#### 56 Introduction

57 The severe acute respiratory syndrome (SARS) pandemic caused by the SARS-coronavirus-19 58 type 2 (SARS-CoV-2) has resulted in about (as of 5:01pm CET, 11 November 59 2022) 630,832,131 confirmed cases of COVID-19, including 6,584,104 deaths, reported to 60 WHO[1]. The pandemic has afflicted all population groups, including children, adolescents, 61 and young adults (AYA), despite their milder course[2]. Children and AYA with comorbidities 62 such as chronic lung disorders, obesity, cardiovascular disease, kidney disease, solid organ 63 transplant, malignancies, or rheumatic diseases, as demonstrated in adult populations, have a 64 higher risk of severe diseases with outcomes such as multi-system inflammatory syndrome in children (MIS-C), intensive care unit (ICU) or life support needs, and increased hazards of 65 66 death[3-7]. Furthermore, COVID-19 clinical presentation in AYA with comorbidities is uncommon and may not follow the conventional epidemiological profile. AYA with 67 68 comorbidities, for example, may acquire MIS-C even after a moderate illness, especially if they 69 have already been exposed to an infected adult[8,9]. AYA with Down syndrome face an 70 additional risk due to their low immunity, putting them at risk of getting serious COVID-19-71 related disorders[10]. Similarly, certain comorbidities may expose AYA to a more severe form 72 of SARS-CoV-2 than others. According to global cancer data, 20% of children with cancer acquire severe SARS-CoV-2 infection[9]. 73

74

75 Vaccination is a well-established method for preventing severe disease development 76 throughout the life course, particularly in persons with chronic and immune-compromising 77 medical illnesses or at increased risk of infection owing to immunosenescence. The flu vaccine, for example, is associated with a significant reduction in the risk of hospitalization for influenza 78 79 illnesses in a predominantly elderly population[11], and the Haemophilus influenzae type b (Hib) vaccine has significantly improved the survival of children with sickle cell disease living 80 81 in low-income countries[12]. To combat the COVID-19 pandemic and its harmful 82 consequences, safe and effective vaccines were developed and licensed first for adults, and 83 subsequently approved for AYA under the age of 16. In AYA, messenger-RNA (m-RNA) 84 vaccines such as BNT162b2 (Pfizer-BioNTech) that encode the SARS-CoV-2 full-length spike 85 responsible for severe acute respiratory syndrome are commonly employed. As of 8 November 2022, a total of 12,885,748,541 vaccine doses have been administered[1]. Serious adverse 86 87 effects were uncommon in randomised clinical trials (RCTs) involving AYA participants, and 88 vaccination effectiveness was near to 100 percent[13,14]. RCT data, on the other hand, are less 89 likely to match real-world data as people with comorbidities are much less likely to be enrolled

in RCTs. Furthermore, in post-marketing studies, the BNT162b2 vaccine was associated to adverse events following immunization (AEFI) not recorded in RCTs, such as myocarditis[15],

92 and vaccination effectiveness differed from that observed in RCTs[16]. It is also recognized 93 that vaccine-preventable diseases are more likely to be severe in people with 94 immunocompromised conditions, and that these people are more likely to be hesitant to receive 95 vaccines. Unfortunately, low immunization rates in these categories are also caused by 96 healthcare practitioners' fails to implement recommendations[17].

97

90

91

98 Considering the paucity of data in immunocompromised AYA, we thoroughly examined the 99 evidence from post-marketing surveillance to assess the effectiveness, safety, and tolerability 100 of the BNT162b2 vaccine against SARS-CoV-2 in AYA to enable for data-driven policy 101 decision making.

### 102 Materials and Methods

103

### 104 Criteria for considering studies for this review

105

## 106 **Types of studies**

107 Non-randomized interventional studies (post-authorization surveillance data), independent of 108 method or unit of allocation, were included, as were observational studies, such as cohort 109 studies (both prospective and retrospective), case-control studies, and cross-sectional studies. 110 Participants in the included studies could be followed up on for any length of time. We considered studies that included a subset of eligible participants (e.g., children and adolescents) 111 112 if the results for the eligible subset of participants were published separately. If this was not possible, such studies were included if 90% or more of the sample was AYA. We omitted 113 114 reviews, case series, and case reports, as well as non-human subject studies. Studies involving 115 children under the age of ten or individuals above the age of twenty-four were also barred.

116

### 117 **Types of interventions**

We included studies investigating any injectable BNT162b2 vaccine intended for the prevention, or mitigation of symptoms, of SARS-CoV-2-infection. All studies involving one or more primary doses (usually doses 1 or 2) and boosters of the BNT162b2 vaccine were eligible for inclusion. Studies were included if interventions were compared with or without a

- 122 placebo vaccine or with another SARS-CoV-2 vaccine. Studies reporting on different COVID-
- 123 19 vaccinations only or predominantly were also excluded (mRNA1273, CoronaVac, etc.).
- 124

#### 125 **Types of outcomes**

126 The outcomes of interest were broadly classified as vaccination i) safety profile (defined in 127 supplemental table 1), ii) tolerability, and iii) efficacy or effectiveness.

#### 128 Search methods for the identification of studies

129 We used a comprehensive search strategy designed to identify the maximum number of eligible 130 studies regardless of language or publication status within a restrictive timeframe. To maximize sensitivity, the techniques did not differentiate between "safety" and "efficacy or 131 effectiveness". Records were identified through a systematic search of MEDLINE (PubMed), 132 133 Embase (Ovid), Web of Science and Cochrane library (CENTRAL). The search was initially 134 designed for MEDLINE (PubMed), but it has since been adapted for use with other sources. 135 PubMed search approach is detailed in **box 1** of the supplemental materials. Other sources such 136 as references of included studies, the WHO database, and the Centres for Disease Control and 137 Prevention (CDC) website as well as the Advisory Committee on Immunization Practices 138 (ACIP) meetings were also searched to identify any references to additional studies that could 139 be potentially eligible. The search began on February 15, 2022, and proceeded on the 15th of 140 each month until May 30, 2022.

141

### 142 **Data collection and analysis**

#### 143 **Selection of studies**

144 Covidence software (Veritas Health Innovation, Melbourne, Australia) was used to import all 145 search results. For de-duplication and screening methods, see www.covidence.org. To select 146 potentially relevant full studies, two reviewers independently examined titles and abstracts. 147 Any disagreements between reviewers were handled through dialogue, with a third reviewer making the final decision. For each record deemed possibly eligible, full text reports were 148 149 obtained. Two reviewers separately screened these full texts to identify research for inclusion 150 in the review, with any disagreements resolved by consensus discussion with the assistance of 151 a third reviewer. The rationale for not including full-text reports was documented. When a full 152 report of a study (e.g., conference proceedings) was not accessible and there was insufficient material for inclusion, the study was labeled as 'awaiting categorization' until the next search 153 154 update. Preprint papers were not included unless they were peer reviewed at the time of the last

155 search. A PRISMA flow diagram was used to document and summarize the flow of156 experiments (Figure 1).

### 157 Data extraction and management

A single reviewer extracted study characteristics and outcomes data, which was then crosschecked by a second reviewer to ensure consistency. The extractions were conducted in Covidence utilizing a pre-piloted extraction form. A table of characteristics of included studies was created utilizing descriptive information extracted from studies and exported from Covidence into an excel document.

### 163 Assessment of risk of bias in included studies

164 Two reviewers assessed the risk of bias (RoB) of included studies using the Cochrane RoB tool[18] for randomized evidence, and the ROBINS-I tool[19] for non-randomized studies. 165 166 One senior reviewer conducted all RoB assessments as the independent duplicate reviewer. Standard domains for each tool were used, and an overall risk of bias was determined using a 167 168 worst-domain scenario approach. As a result, we judged the overall risk of bias for each study as 'low risk', 'unclear risk' or 'high risk' and reported the main reason in the summary table 169 170 for RoB. Any discrepancies in individual domain judgments as well as overall judgements were 171 resolved through consensus or adjudication by a third review author.

172

## 173 Statistical analysis

174 Stata 16.0 was used to conduct the meta-analyses (Stata corp., College Station, TX, USA). To 175 account for study heterogeneity, the random effects model estimated pooled proportion, log 176 RR, and mean difference with 95 % confidence intervals (CI). To quantify heterogeneity, I<sup>2</sup> 177 statistics were utilized. All analyses were initially performed in comparison to the 178 administration of the first and second doses of BNT162b2 vaccines. Subgroup analyses were 179 then performed, which comprised rheumatic illnesses, severe neurodisabilities, Down 180 syndrome, type 1 diabetes, cystic fibrosis, and solid tumours. Finally, the combined effect of 181 the first and second doe was investigated. When the standard error (SE) in a study was not 182 published, we determined it from the proportion using the formula: SE = P (1-P)/N and 95 % CI = P 1.96 SE, where P was the proportion and N was the sample size comprising 183 184 immunocompromised adolescents[20]. Studies that reported the median and IQR were converted to mean (SE)[21], and BAU/ml or U/ml to AU/ml using online computations. A 185 186 meta-regression was also performed on the local and systemic reactions. Because the review

187 comprised less than ten studies from all forest plots, Egger's regression analysis and Begg's

- 188 rank correlation analysis were used to investigate the probability of publication bias.
- 189
- 190 **Results**
- 191

### 192 **Characteristic of included studies**

193 Of the 443 records found in the various data bases analyzed, 47 full texts were carefully 194 reviewed for eligibility, and nine studies were included (Figure 1). Rheumatic disorders were 195 studied in four studies, and type 1 diabetes, Down syndrome, solid tumor, neurodisability, and 196 cystic fibrosis were studied in one each. Eight studies (Akgün 2022; Dimopoulou 2022; 197 Heshin-Bekenstein 2022; King 2022; Michos 2022; Piccini 2022; Riviere 2021; Valentini 2022)[3,4,8-10,22-24] employed a cohort design, whereas one used a cross-sectional 198 199 design(Haslak 2022)[6]. Most investigations were undertaken in Europe (Supplementary 200 Table 2).

201

#### 202 **Risk of bias**

203 The assessment of RoB for these studies was conducted using ROBINS-I (Supplementary 204 Table 3). Six studies had an unclear overall risk of bias (Akgün 2022; Dimopoulou 2022; 205 Haslak 2022; King 2022; Piccini 2022; Riviere 2021). None of these studies could rule out 206 selection bias, ascertainment bias, or selective outcome reporting. Bias due to confounding 207 could also not be ruled out in four studies (Akgün 2022; King 2022; Piccini 2022; Riviere 208 2021); while bias in the classification of interventions could not be ruled out in two (Haslak 209 2022; Piccini 2022); deviations from intended interventions could not be ruled out in five 210 (Akgün 2022; Dimopoulou 2022; King 2022; Piccini 2022; Riviere 2021); and attrition bias 211 could not be ruled out in four (Akgün 2022; Dimopoulou 2022; King 2022; Piccini 2022). 212 Furthermore, three (Akgün 2022; Haslak 2022; Riviere 2021) had other sources of bias 213 identified – this related mostly to small sample sizes and short post-vaccination follow-up.

214

215 Three studies had a high overall risk of bias (Heshin-Bekenstein 2022; Michos 2022; Valentini 216 2022). Three studies were at high risk of bias due to confounding (Heshin-Bekenstein 2022; 217 Michos 2022; Valentini 2022); one was at high risk of attrition bias (Heshin-Bekenstein 2022); 218 and one was at high risk of ascertainment bias (Heshin-Bekenstein 2022). Selection bias, bias 219 due to deviations from intended interventions and selective outcome reporting could not be

220 ruled out in any of these studies; bias in the classification of interventions could not be ruled

out in two studies (Michos 2022; Valentini 2022), attrition bias could not be ruled out in one

222 (Michos 2022), and ascertainment bias could not be ruled out in two studies (Michos 2022;

- 223 Valentini 2022).
- 224

### 225 Any local AEFI

226

227 Figure 2A shows the tolerability of dose 1 BNT162b2 vaccine among adolescents. 228 Immunocompromised conditions include rheumatic diseases, severe neurodisabilities, Down 229 syndrome, type 1 diabetes, and solid tumours, with an overall pooled proportion of any local 230 reaction of 28%[95% CI: 11%-44%]. The following local reactions were observed among the 231 six studies included in the pooled results: pain, swelling, itching, and erythema. The subgroup 232 analysis revealed that diabetes mellitus type 1 adolescents had the highest rate of any local 233 proportion reactions 72%[95%CI: 56%-87%], solid tumours (46%[95%CI: 19%-73%], rheumatic diseases (27%[95%CI: 4%-50%], down syndrome (13%[95%CI: -9%-35%], and 234 severe neurodisabilities 4%[95%CI: -4%-11%]. The summary effect or pooled proportional 235 236 estimate of any local reaction following the second dose of BNT162b2 vaccine among 237 immunocompromised adolescents was found to be 23% [95% CI: 10%-37%]. Pain, swelling, 238 erythema, itching, and pruritus were the most common local reactions following dose 2 of the 239 BNT162b2 vaccine. Adolescents with type 1 diabetes had the highest pooled estimate of any local reaction (64% [95%CI: 49%-79%], followed by rheumatic diseases (23% [95%CI: 6%-240 241 41%], solid tumours 15% [95%CI: -4%-35%], Down syndrome 14% [95%CI: -5%-34%], and 242 severe neurodisabilities 9% [95%CI: -0.3%-21%] (Figure 2B).

243

### 244 Any systemic AEFI

245 The most common systemic reactions after dose 1 in the meta-analysis evaluating any systemic 246 reaction following administration of BNT162b2 vaccine in immunocompromised adolescents 247 were fever, muscle ache, headache, fatigue, running nose, joints pain, chills, feeling unwell, hospitalization, weakness, exacerbation, nausea, and vomiting, with an overall pooled 248 249 proportion of 9%[95%CI: 6%-11]. Adolescents with diabetes mellitus and those with severe 250 neurodisabilities had the highest incidence of systemic reactions, at 20%[95% CI: 6%-32%] 251 and 20%[95% CI: 6%-36%], respectively. The proportion of adolescents with systemic reactions among those with solid tumour was 12% [95%CI: 2%-22%], while those with 252

253 rheumatic diseases and Down syndrome had 6% [95%CI: 5%-10%] and 3% [95%CI: 1%-6%],

254 respectively (**Figure 3A**).

255

256 The overall pooled proportion of any systemic reaction after dose 2 of BNT162b2 vaccine was 257 13% [95% CI: 10%-17%]. Fever, muscle ache, headache, fatigue, running nose, joint pain, 258 chills, feeling unwell, hospitalization, weakness, exacerbation, nausea, and vomiting were 259 among the common systemic reactions observed. As with the first dose, adolescents with diabetes mellitus exhibited the highest proportion of systemic reactions 27%[95%CI: 15%-260 40%], followed by those with solid tumour 23%[95%CI: 3%-43%], severe neurodisabilities 261 262 17%[95%CI: 6%-20%] then by those with rheumatic diseases 12%[95%CI: 9%-16%] and 263 Down syndrome 4% [95% CI: 1%-7%] (Figure 3B).

264

# 265 Any local and systemic AEFI

The overall proportion of combined AEFIs in immunocompromised adolescents in studies that 266 267 reported on combined systemic and local AEFIs following the first dose of BNT162b2 vaccination was 30%[% CI: 17% - 42%]. A high proportion of AEFIs was observed among 268 269 adolescents with rheumatic diseases 51% [95%: 32%-70%], solid tumours 33%[95%CI: 11%-270 56%], Down syndrome 18%[95%CI: 6%-30%], and cystic fibrosis 17%[95%CI: 5%-29%] 271 (Figure 4A). Further, among adolescents, the overall proportion of combined systemic and 272 local reactions following the second dose of BNT162b2 was 32% [95% CI: 19%-44%]. A high 273 proportion of reactions was observed in adolescents with rheumatic diseases 40% [95%: 16%-274 65%] followed by those with solid tumours 25%[95%CI: 3%-45%], Down syndrome 275 19%[95%CI: 10%-29%], and cystic fibrosis 27%[95%CI: 17%-38%] (Figure 4B).

276

### 277 Antibody responses

278 The comparison of antibodies neutralization after dose 1 BNT162b2 vaccine between 279 immunocompromised adolescents (cystic fibrosis and Down syndrome) and healthy adults was 280 assessed in two studies. The pooled log RR revealed no statistically significant differences between the two groups, with a Log RR of 0.08 (95% CI: -0.16, 0.32, p=1,  $I^2 = 0.00\%$ ) (Figure 281 282 5A). The comparison of antibodies neutralization after dose 2 of BNT162b2 vaccine among immunocompromised adolescents (rheumatic diseases and cystic fibrosis) and healthy adults 283 284 included two studies. The pooled log RR revealed no statistically significant differences between the two groups, with a Log RR of -0.00 (95% CI: -0.24, 0.24, p=0.52, I<sup>2</sup>=0.00%) 285 286 (Figure 5B).

287

288 The effectiveness of BNT162b2 vaccine after dose 1 in quantifying IgG (AU/ml) was reported 289 in two studies. Valentini et al.[10] measured IgG levels in adolescents known with Down 290 syndrome and in healthy adolescents after 21, 28, and 180 days, with mean differences (MD) 291 IgG (AU/ml) of 146.69 (95% CI: 68.59 to 224.79), -36.99 (95% CI: -59.13 to -14.85), and -292 1430.97 (95% CI: -1976.65 to -885.29). MD IgG was -405.24 (95% CI: -1345.59 to 535.12) 293 after 21 and 180 days. Michos et al.[24] found an MD IgG of 187.14 (95% CI: -94.10 to 468.38) 294 among cystic fibrosis vs healthy adolescents. While healthy adolescents had higher IgG -248.25 (95% CI: -954.51 to 458.01, p=0.24,  $I^2 = 99.53\%$ ), the overall pooled MD IgG was not 295 296 statistically different between the two groups (Figure 6A). For the second dose, Valentini et 297 al.[10] measured IgG levels in Down syndrome and healthy adolescents after 28, 45, and 180 298 days, with mean differences (MD) IgG (AU/ml) of -57.62(95%CI:-115.91 to 068), 299 0.00(95%CI: -38.16 to 38.16), and -692.74(95%CI: -719.63 to -685.85), respectively. MD IgG 300 was -250.53 (95% CI: -686.01 to 184.96) over 28 and 180 days. In comparison, Heshin-Bekenstein et al.[4] reported a MD IgG of -56.08 (95% CI: -79.18 to -32.98) among rheumatic 301 302 diseases vs healthy adolescents. Even though healthy adolescents had higher, the overall 303 pooled MD IgG was not statistically different between the two groups, IgG -201.91 (95% CI: -524.28 to 120.45, p=0.38, I<sup>2</sup> = 99.74%) (Figure 6B). 304

305

#### 306 **Publication bias**

307 We assessed publication bias using regression tests with a random-effects model for included 308 studies. As we performed statistical tests, publication bias was less likely for any local reaction 309 after the second dose of BNT162b2, and no evidence of publication bias was observed for 310 Egger's regression analysis (P = 0.02). Begg's rank correlation analysis, on the other hand, 311 yielded a p-value of 0.003. In contrast, publication bias was clearly present for any systemic 312 reaction following the second dose of BNT162b2 (P<0.001) for Egger's regression analysis 313 and p<0.001 for Begg's rank correlation analysis).

314

#### 315 Discussion

316 In this systematic review and meta-analysis of mostly post-marketing studies, we found that the humoral response to BNT162b2 vaccine in AYA with various comorbidities resulting in a 317 318 compromised immune system was effective after the second dose with an acceptable safety 319 profile and without exacerbating the disease condition or causing severe adverse reactions. 320

321 Many studies have reported that AYA with rheumatic diseases, severe neurological disorders, 322 Down syndrome, type 1 diabetes, and solid tumours who received first doses of the vaccination 323 reported mostly local reactions; the number of participants who developed AEFIs increased 324 after the second dose. These findings are consistent with those of a randomised trial in Japanese 325 people, in which systemic events rose from 1% to 4% after the second dose[25]. Instead, some 326 studies found conflicting results regarding neurological complications such as Guillain-Barre 327 syndrome and Bell's palsy related with the ChAdOx1 and CoronVac vaccinations but not the 328 BNT162b2 vaccine[26].

329

330 Specificity associated with each ailment may be communicated to health care providers and 331 caregivers. While local AEFIs were prevalent, AYA with diabetes mellitus had a higher 332 proportion of reports of local response. Diabetes mellitus has been linked to a wide range of 333 dermatologic disorders, many of which improve with glycaemic control[27]. As a result, it is critical to maintain appropriate diabetes management prior to delivering BNT162b2 334 335 vaccinations in order to limit the risk of morbidity. Systemic responses, such as fever, were 336 also more common in those with diabetes, probably for the same reasons mentioned above. 337 However, no major severe adverse events requiring hospitalization were reported, such as 338 diabetic ketoacidosis or severe hypoglycaemia. Furthermore, modest adverse effects similar to 339 those described in the general population were observed in adolescents with type 1 diabetes 340 mellitus who were on different medications and monitoring systems.

341

342 Surprisingly, AYA with Down syndrome exhibited the lowest proportion of systemic 343 responses, although having mild to moderate T cell and B cell lymphopenia and concomitant 344 T cell abnormalities. This suggests that children and adolescents with Down syndrome have an 345 excellent safety and tolerability profile. Another study found that when AYA with juvenile 346 idiopathic arthritis (JIA) were given tumour necrosis factor inhibitors, the adverse responses 347 were more common after the second dose than the first. However, no illness exacerbations occurred post vaccination[22]. Another study has reported that the vaccine had similar safety 348 349 profiles, with minimal side effects occurring at a similar frequency in both adolescents with 350 juvenile-onset autoimmune inflammatory rheumatic disorders (AIIDRs) and controls[4]. 351 Systemic symptoms such as fever after the first dosage, as well as weariness, myalgia, and 352 arthralgia after the second dose, were more common in adolescents with AIIDRs than in the 353 control group, but the difference was not statistically significant. Furthermore, small increases 354 in disease deterioration were observed, but following the first and second doses, 94.4% and

98.8% of patients maintained stable disease activity with no worsening, respectively. Asinstance, our findings suggest that patients with AIIRDs have acceptable safety profiles.

357

358 When antibody responses were compared after vaccination doses, there was an adequate IgG 359 response mounted by the immune systems of AYA with the immunocompromised diseases 360 under consideration, according to studies reporting antibody neutralization after first and 361 second doses of vaccine. It should be highlighted that patients who tested positive for SARS-362 CoV-2 before to vaccination had higher IgG titers than those who tested negative (P=0.20), 363 implying that patients who had previously been exposed to COVID-19 acquire more persistent 364 and strong antibodies than naive patients. Considering that reinfection leading to natural 365 immunity can be dangerous for AYA with comorbidities, it is fortunate that the second vaccine dosage exhibited comparable outcomes in increasing anti-DBD IgG titers in children receiving 366 367 either conventional disease-modifying anti-rheumatic medications (cDMARDs) or biological DMARDs. Furthermore, no association was found between gender and vaccine reaction. 368 369 However, treatment patterning to comorbidities affected immunologic responses to the vaccine 370 in some cases, with lower immunologic responses observed in adolescents receiving combined 371 therapy (conventional and biological therapy); this difference was statistically significant when compared to the biological therapy group. Despite their low levels, these youngsters were able 372 373 to obtain immunizations without halting their treatment.

374

375 Some conditions not included in this meta-analysis are also of particular attention to inform 376 decision making. For example, older adolescents with a median age of 19 years receiving an 377 immunosuppressive regimen for a kidney transplant had poorer immunogenicity responses, 378 with only 52% of patients showing the presence of spike antibodies after the second dose of 379 the BNT162b2 mRNA at 4 to 8 weeks (median of 45 days), whereas younger patients in the 380 study tended to present with better immunogenicity responses[28]. Patients on Mycophenolate Mofetil (MMF), a medication that inhibits antibody production, had the lowest 381 382 immunogenicity responses. Clarkson et al.[28] reported equally modest immunogenicity 383 responses in his cohort of patients who were also on MMF. A Canadian study looked at allergic 384 reactions to PEG-asparaginase (PEG-ASNase), a component of BNT162b2, in 32 patients aged 385 12 and above who had a history of grade 2-4 allergy to PEG-ASNase, according to the Common 386 Terminology Criteria for Adverse Events (CTCAE)[7]. However, no adverse reaction was seen 387 30 minutes following delivery of the vaccine. Data on adolescents with other comorbidities, 388 particularly those prevalent in low-income countries, such as sickle cell anaemia, malnutrition,

and HIV infection, is scarce. HIV is known to cause immunological dysregulation in adults,
children, and adolescents and has the highest prevalence in Sub-Saharan Africa2023/01/20
10:56:00

392

393 It should be highlighted that the majority of included studies had an unclear overall risk of bias, 394 while the rest had a high overall risk. As a result, the whole evidence base covered in this 395 assessment has methodological limitations. While it is true that many of these studies were 396 carried out during the height of the pandemic, when extraordinary and often emergency-397 response circumstances prevailed, future studies should aim to address or mitigate these 398 limitations. This could be accomplished by addressing several difficulties. To begin, studies 399 with comparative results (two or more arms) should be carefully adjusted to account for 400 potential confounders, while also making an effort to recruit a comparable control group to 401 reduce the chance of false findings. Such comparison evidence is desirable, but if a single-arm 402 study is required, the data should be stratified by potential effect modifiers and confounders to 403 investigate their impact on the outcomes. Second, detailed reporting of participant selection as 404 well as if - and how - vaccination status was confirmed is necessary, as confusion in these 405 domains is frequently caused by a lack of reported data. This data should describe the inclusion 406 of a diverse group of patients who match the eligibility requirements; convenience selection 407 should be avoided to reduce the possibility of volunteer bias. Furthermore, there must be 408 explicit reporting of the measures used and sources consulted to ensure vaccination status. 409 Third, attrition should be reduced to the greatest extent practicable by follow-up and assuring 410 the availability of data-generating resources. Where attrition is unavoidable, it should be clearly 411 recorded as individuals lost to follow-up or with missing data from the initial eligible sample, 412 along with reasons, and suitable statistical procedures should be employed to account for 413 missing data where substantial attrition is encountered. Exclusions based on the investigator should be kept to a minimum as well. Fourth, the determination of outcomes, particularly safety 414 415 outcomes, should be standardised and objectively assessed. This is especially significant in 416 comparative studies, because subjective participant-reported metrics may lead to erroneous 417 nocebo effects. Fifth, any future studies should have clear prospective *a priori* protocols or 418 statistical analysis plans in place to allow for an assessment of the risk of bias associated with 419 probable selective outcomes presented. While it is recognized that the relative rarity of the 420 conditions studied in the review may result in small sample sizes, this should be avoided to the 421 greatest extent possible by including larger groups of potentially eligible participants to 422 improve generalisability and reduce the risk of fragile or chance findings.

423

### 424 Conclusion

425 AYA with rheumatic disorders, severe neurodisabilities, Down syndrome, type 1 diabetes, and 426 solid tumours who received the COVID-19 BNT162b2 mRNA vaccine showed good 427 immunogenicity and safety. While illness specificity should be recognized to guide practice, 428 there is an urgent need to improve the design of post-marketing studies of AYA with 429 comorbidity, as well as research on comorbidities that are prevalent in low-resource settings, 430 such as HIV infection, to ensure vaccine equality.

431

### 432 **Contributors**

- 433 PK, CSW and GG conceived the study. PK, LB and MM did the literature search. PK and LB
- 434 did the study selection. JT, LB, AB, and PK extracted the relevant information. PK accessed
- 435 and verified the data. AB supervised the risk of study section. PK and JT synthesized the data.
- 436 PK, MM, AA, LB and AB wrote the first draft. CSW and GG supervised the overall work. All
- 437 authors critically revised successive drafts of the paper. All authors had full access to all the
- data in the study, read, and approved the final manuscript, and had final responsibility for the 438
- 439 decision to submit for publication
- 440

### **Declaration of interests** 441

442 All authors declare no competing interests.

#### 443 **Data sharing**

444 All data generated or analysed during this study are included in this published Article and the 445 appendix.

### 446 Acknowledgments

447 We acknowledge the South African Medical Research Council for supporting the work of some

- 448 of the authors and for providing funding for open access publication of this study.
- 449

### 450 References

- [1] WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2022 Nov 14]. Available 451 452 from: https://covid19.who.int.
- 453 COVID-19 disease in children and adolescents: Scientific brief, 29 September 2021 [2] 454 [Internet]. [cited 2022 Nov 14]. Available from: https://www.who.int/publicationsdetail-redirect/WHO-2019-nCoV-Sci Brief-Children and adolescents-2021.1. 455


medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284812; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity.	
It is made available under a CC-BY-NC 4.0	) International license .

456 [3] Akgün Ö, Çakmak F, Guliyeva V, et al. Humoral response and safety of BNT162b2 457 mRNA vaccine in children with rheumatic diseases. Rheumatology (Oxford). 458 2022;61:4482-4490. 459 Heshin-Bekenstein M, Ziv A, Toplak N, et al. Safety and immunogenicity of BNT162b2 [4] 460 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with 461 immunomodulatory medications. Rheumatology (Oxford). 2022;keac103. 462 [5] Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large 463 HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 464 2011;25:185-195. 465 [6] Haslak F, Gunalp A, Cebi MN, et al. Early experience of COVID-19 vaccine-related 466 adverse events among adolescents and young adults with rheumatic diseases: A single-467 center study. Int J Rheum Dis. 2022;25:353–363. 468 [7] Mark C, Gupta S, Punnett A, et al. Safety of administration of BNT162b2 mRNA 469 (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of 470 acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer. 471 2021;68:e29295. 472 [8] Piccini B, Pessina B, Pezzoli F, et al. COVID-19 vaccination in adolescents and young 473 adults with type 1 diabetes: Glycemic control and side effects. Pediatr Diabetes. 2022; 474 Revon-Riviere G, Ninove L, Min V, et al. The BNT162b2 mRNA COVID-19 vaccine in [9] 475 adolescents and young adults with cancer: A monocentric experience. Eur J Cancer. 476 2021;154:30-34. 477 [10] Valentini D, Cotugno N, Scoppola V, et al. Safety and Long-Term Immunogenicity of 478 BNT162b2 Vaccine in Individuals with Down Syndrome. J Clin Med. 2022;11:694. 479 [11] Tenforde MW, Talbot HK, Trabue CH, et al. Influenza Vaccine Effectiveness Against 480 Hospitalization in the United States, 2019–2020. The Journal of Infectious Diseases. 481 2021;224:813-820. 482 [12] Allali S, Chalumeau M, Launay O, et al. Conjugate Haemophilus influenzae type b 483 vaccines for sickle cell disease. Cochrane Database Syst Rev. 2018;8:CD011199. 484 [13] Thomas SJ, Moreira EDJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 485 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385:1761–1773. 486 [14] Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA 487 Covid-19 Vaccine. N Engl J Med. 2020;383:2603-2615. 488 [15] Gargano JW. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among 489 Vaccine Recipients: Update from the Advisory Committee on Immunization Practices 490 — United States, June 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 491 2022 Feb 7];70. Available from: 492 https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm. 493 [16] Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-494 BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated

- 495 Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION 496 497 Network, 10 States, April 2021–January 2022. MMWR Morb Mortal Wkly Rep. 498 2022;71:352-358.
- 499 [17] Doherty M, Schmidt-Ott R, Santos JI, et al. Vaccination of special populations: Protecting the vulnerable. Vaccine. 2016;34:6681-6690. 500
- 501 [18] Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for 502 assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
- 503 [19] Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in 504 non-randomised studies of interventions. BMJ. 2016;355:i4919.
- [20] Shi J, Luo D, Weng H, et al. Optimally estimating the sample standard deviation from 505 506 the five-number summary. Res Synth Methods. 2020;11:641-654.
- 507 [21] Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, 508 median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785-509 1805.
- [22] Dimopoulou D, Spyridis N, Vartzelis G, et al. Safety and tolerability of the COVID-19 510 511 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with 512 tumor necrosis factor inhibitors. Arthritis Rheumatol. 2022;74:365-366.
- 513 [23] King H, Deshpande S, Woodbridge T, et al. Initial experience of the safety and 514 tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable 515 children aged 12-15 years. Arch Dis Child. 2022;107:205-207.
- [24] Michos A, Filippatos F, Tatsi E-B, et al. Immunogenicity of the COVID-19 BNT162b2 516 517 vaccine in adolescents and young adults with cystic fibrosis. J Cyst Fibros. 518 2022;21:e184-e187.
- 519 [25] Haranaka M, Baber J, Ogama Y, et al. A randomized study to evaluate safety and 520 immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat 521 Commun. 2021;12:7105.
- 522 [26] Ab Rahman N, Lim MT, Lee FY, et al. Risk of serious adverse events after the 523 BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case 524 series study. Vaccine. 2022;40:4394-4402.
- [27] Labib A, Rosen J, Yosipovitch G. Skin Manifestations of Diabetes Mellitus. In: 525 526 Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth 527 (MA): MDText.com, Inc.; 2000 [cited 2022 Nov 15]. Available from: 528 http://www.ncbi.nlm.nih.gov/books/NBK481900/.
- 529 [28] Crane C, Phebus E, Ingulli E. Immunologic response of mRNA SARS-CoV-2 530 vaccination in adolescent kidney transplant recipients. Pediatr Nephrol. 2022;37:449-531 453.
- 532

### **Figures**



539 Figure 1: Study PRISMA flow char	539	Figure	1: Study	<sup>PRISMA</sup>	flow char
--------------------------------------	-----	--------	----------	-------------------	-----------

A	Effect Size with 95% Cl	Weight (%)
Rheumatic diseases		. ,
Akgun 2022 (Pain)	0.59 [ 0.43, 0.74]	7.50
Akgun 2022 (Swelling)	0.49 [ 0.33, 0.64]	7.48
Akgun 2022 (Erythema)	0.02 [ -0.02, 0.07]	7.94
Akgun 2022 (Itching)	0.02 [ -0.02, 0.07]	7.94
Bekenstein 2022 (Pain)	- 0.87 [ 0.80, 0.94]	7.88
Bekenstein 2022 (Swelling)	- 0.12 [ 0.05, 0.19]	7.89
Bekenstein 2022 (Erythema)	0.03 [ -0.00, 0.07]	7.96
Bekenstein 2022 (Itching)	0.04 [ 0.00, 0.09]	7.95
Heterogeneity: $\tau^2 = 0.11$ , $I^2 = 99.23\%$ , $H^2 = 130.39$	0.27 [ 0.04, 0.50]	
Test of $\theta_i = \theta_j$ : Q(7) = 560.97, p = 0.00	- · · · ·	
Severe neurodisabilities		
King 2022 (Erythema)		7.87
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$	• 0.04 [ -0.04, 0.11]	
Test of $\theta_i = \theta_j$ : Q(0) = -0.00, p = .		
Down syndrome		
Valentini 2022 (Pain)		7.59
Valentini 2022 (Erythema)	0.03 [ -0.02, 0.07]	7.94
Heterogeneity: $\tau^2 = 0.02$ , $I^2 = 89.54\%$ , $H^2 = 9.56$	0.13 [ -0.09, 0.35]	
Test of $\theta_i = \theta_j$ : Q(1) = 9.56, p = 0.00		
Type 1 diabetes mellitus		
Piccini 2022 (Pain)	0.72 [ 0.56, 0.87]	7.47
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$	0.72 [ 0.56, 0.87]	
Test of $\theta_i = \theta_j$ : Q(0) = 0.00, p = .		
Solid tumour		
Riviere 2021 (Pain)	0.46 [ 0.19, 0.73]	6.59
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$	0.46 [ 0.19, 0.73]	
Test of $\theta_i = \theta_j$ : Q(0) = -0.00, p = .		
Overall	0.28 [ 0.11, 0.44]	
Heterogeneity: $\tau^2 = 0.09$ , $I^2 = 98.85\%$ , $H^2 = 86.88$		
Test of $\theta_i = \theta_j$ : Q(12) = 646.94, p = 0.00		
Test of group differences: $Q_b(4) = 65.70$ , p = 0.00		
	0 .5 1	
Random-effects REML model		

Study Rheumatic diseases Akgun 2022 (Pain)		(%)
Akgun 2022 (Pain)		. ,
		5.96
Akgun 2022 (Swelling)	0.05 [ -0.02, 0.11]	6.35
Akgun 2022 (Erythema)	0.02 [ -0.02, 0.07]	6.40
Akgun 2022 (Itching)	0.02 [ -0.02, 0.07]	6.40
Bekenstein 2022 (Pain)	0.73 [ 0.63, 0.82]	6.26
Bekenstein 2022 (Swelling)	0.09 [ 0.03, 0.15]	6.37
Bekenstein 2022 (Erythema)	0.02 [ -0.01, 0.05]	6.43
Bekenstein 2022 (Itching)	0.03 [ -0.00, 0.07]	6.42
Bekenstein 2022 (Pruritus)	0.01 [ -0.01, 0.03]	6.44
Dimopoulou 2022 (Pain)	0.50 [ -1.01, 2.01]	0.69
Dimopoulou 2022 (Swelling)	0.29 [ 0.15, 0.42]	6.04
Dimopoulou 2022 (Erythema)	0.74 [ 0.61, 0.87]	6.06
Heterogeneity: τ² = 0.09, Ι² = 99.22%, Η² = 128.58		
Test of $\theta_i = \theta_j$ : Q(11) = 385.33, p = 0.00	•	
Severe neurodisabilities		
King 2022 (Erythema)	0.09 [ -0.03, 0.21]	6.13
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$	• 0.09 [ -0.03, 0.21]	
Test of $\theta_i = \theta_j$ : Q(0) = 0.00, p = .		
Down syndrome		
Valentini 2022 (Pain)		6.06
Valentini 2022 (Erythema)	0.05 [ -0.02, 0.12]	6.35
Heterogeneity: $\tau^2 = 0.02$ , $I^2 = 85.31\%$ , $H^2 = 6.81$	• 0.14 [ -0.05, 0.34]	
Test of $\theta_i = \theta_j$ : Q(1) = 6.81, p = 0.01		
Type 1 diabetes mellitus		
Piccini 2022 (Pain)	0.64 [ 0.49, 0.79]	5.96
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$	• 0.64 [ 0.49, 0.79]	
Test of $\theta_i = \theta_j$ : Q(0) = 0.00, p = .		
Solid tumour		
Riviere 2021 (Pain)		5.67
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$	• 0.15 [ -0.04, 0.35]	
Test of $\theta_i = \theta_j$ : Q(0) = 0.00, p = .		
Overall	0.23 [ 0.10, 0.37]	
Heterogeneity: $\tau^2 = 0.07$ , $I^2 = 98.79\%$ , $H^2 = 82.34$		
Test of $\theta_i = \theta_j$ : Q(16) = 452.11, p = 0.00		
Test of group differences: $Q_b(4) = 34.81$ , p = 0.00	· · · · · · · · · · · · · · · · · · ·	
andom-effects REML model	-1 0 1 2	

- Figure 2: Forest plot of the proportion of any local reaction among immune-compromised 544
- 545 adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of
- 546 BNT162b2 vaccine.

AStudy				Effect Size with 95% CI	Weig (%)
Rheumatic diseases					
Akgun 2022 (Fever)				0.12 [ 0.02, 0.22]	2.34
Akgun 2022 (Muscles ache)				0.15 [ 0.04, 0.25]	2.17
Akgun 2022 (Headache)				0.24 [ 0.11, 0.38]	1.75
Akgun 2022 (Fatigue)				0.32 [ 0.17, 0.46]	1.59
Bekenstein 2022 (Fever)				0.05 [ 0.01, 0.10]	3.65
Bekenstein 2022 (Nausea)	-			0.04 [ 0.00, 0.09]	3.77
Bekenstein 2022 (Running nose)	- <b>-</b>			0.03 [ -0.00, 0.07]	3.89
( <b>č</b> )					
Bekenstein 2022 (Muscles aches)				0.10 [ 0.04, 0.16]	3.28
Bekenstein 2022 (Joint pain)	-			0.04 [ 0.00, 0.09]	3.77
Bekenstein 2022 (Chills)	-	_		0.03 [ -0.00, 0.07]	3.89
Bekenstein 2022 (Headache)		-		0.09 [ 0.03, 0.15]	3.36
Bekenstein 2022 (Feeling unwell)				0.11 [ 0.05, 0.17]	3.21
Bekenstein 2022 (Hospitalization)	÷			0.02 [ -0.01, 0.05]	4.03
Bekenstein 2022 (Weakness)		-		0.10 [ 0.04, 0.16]	3.28
Bekenstein 2022 (Fatigue)	-			0.17 [ 0.09, 0.24]	2.90
Bekenstein 2022 (Exacerbation)				0.05 [ 0.01, 0.10]	3.65
Haslak 2021 (Fever)	-	-		0.07 [ 0.04, 0.11]	3.89
Haslak 2021 (Vomiting)	4	-		0.12 [ 0.07, 0.17]	3.67
Haslak 2021 (Voliming) Haslak 2021 (Nausea)		_		0.01 [ -0.00, 0.02]	4.26
Haslak 2021 (Headache)				0.05 [ 0.02, 0.08]	4.20
					4.00
Heterogeneity: $\tau^2 = 0.00$ , $l^2 = 79.79\%$ , $H^2 = 4.95$ Test of $\theta_i = \theta_i$ : Q(19) = 89.31, p = 0.00	▼			0.08 [ 0.05, 0.10]	
Severe neurodisabilities		-		0.401.004.007	4.00
King 2022 (Fever)				0.12 [ -0.01, 0.24]	1.90
King 2022 (Feeling unwell)				0.38 [ 0.20, 0.57]	1.09
King 2022 (Fatigue)				0.15 [ 0.02, 0.29]	1.64
Heterogeneity: $\tau^2 = 0.01$ , $l^2 = 68.74\%$ , $H^2 = 3.20$ Test of $\theta_i = \theta_j$ : Q(2) = 5.83, p = 0.05				0.20 [ 0.05, 0.36]	
Down syndrome					
Valentini 2022 (Fever)		_		0.05 [ -0.02, 0.12]	3.12
Valentini 2022 (Muscles ache)	-			0.03 [ -0.02, 0.07]	3.62
Valentini 2022 (Chills)	_			0.03 [ -0.02, 0.07]	3.62
Valentini 2022 (Headache)				0.03 [ -0.02, 0.07]	3.62
				• • •	
Valentini 2022 (Fatigue)				0.03 [ -0.02, 0.07]	3.62
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.01\%$ , $H^2 = 1.00$ Test of $\theta_i = \theta_i$ : Q(4) = 0.47, p = 0.98	•			0.03 [ 0.01, 0.05]	
Type 1 diabetes					
Piccini 2022 (Fever)				0.13 [ 0.02, 0.23]	2.24
Piccini 2022 (Musches ache)				0.13 [ 0.02, 0.23]	2.24
Piccini 2022 (Headache)		-		0.18 [ 0.06, 0.30]	1.94
Piccini 2022 (Weakness)			-	- 0.41 [ 0.26, 0.56]	1.43
Heterogeneity: τ² = 0.01, l² = 75.60%, H² = 4.10			•	0.20 [ 0.08, 0.32]	
Test of $\theta_i = \theta_j$ : Q(3) = 10.42, p = 0.02					
Solid tumour					
Riviere 2021 (Fever)		-	_	0.15 [ -0.04, 0.35]	1.01
Riviere 2021 (Headache)				0.08 [ -0.07, 0.22]	1.55
Riviere 2021 (Fatigue)				0.15 [ -0.04, 0.35]	1.01
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.00\%$ , $H^2 = 1.00$				0.12 [ 0.02, 0.22]	
Test of $\theta_i = \theta_j$ : Q(2) = 0.57, p = 0.75				···· [ ···· · · · · · · · · · · · · · ·	
Overall		•		0.09 [ 0.06, 0.11]	
Heterogeneity: τ² = 0.00, Ι² = 82.71%, Η² = 5.78				,	
Test of $\theta_i = \theta_j$ : Q(34) = 142.13, p = 0.00					
Test of group differences: $Q_b(4) = 19.64$ , p = 0.00					
	ò	.2	.4	.6	

B		Weight
Study Rheumatic diseases	with 95% CI	(%)
Akgun 2022 (Fever)	0.12 [ 0.02, 0.22]	2.52
Akgun 2022 (Nuscles ache)	0.12 [ 0.02, 0.22]	2.32
Akgun 2022 (Muscles ache) Akgun 2022 (Headache)		2.41
Akgun 2022 (Teadacite) Akgun 2022 (Fatigue)	0.32 [ 0.17, 0.46]	1.99
	_	
Bekenstein 2022 (Fever)		2.82
Bekenstein 2022 (Vomiting)		3.28
Bekenstein 2022 (Nausea)	0.07 [ 0.02, 0.12]	3.09
Bekenstein 2022 (Running nose)	- 0.05 [ 0.00, 0.09]	3.18
Bekenstein 2022 (Muscles ache)	0.22 [ 0.13, 0.30]	2.70
Bekenstein 2022 (Joint pain)		2.94
Bekenstein 2022 (Chills)	0.12 [ 0.06, 0.19]	2.91
Bekenstein 2022 (Headache)	0.25 [ 0.16, 0.34]	2.64
Bekenstein 2022 (Feeling unwell)	0.27 [ 0.18, 0.37]	2.61
Bekenstein 2022 (Hospitalization)	0.01 [ -0.01, 0.03]	3.34
Bekenstein 2022 (Weakness)	0.28 [ 0.19, 0.38]	2.59
Bekenstein 2022 (Fatigue)	0.22 [ 0.13, 0.30]	2.70
Bekenstein 2022 (Exacerbation)	0.01 [ -0.01, 0.03]	3.34
Haslak 2021 (Fever)	0.06 [ 0.03, 0.10]	3.26
Haslak 2021 (Vomiting)	0.03 [ 0.01, 0.06]	3.32
Haslak 2021 (Vornung) Haslak 2021 (Headache)		
, ,		3.24
Haslak 2021 (Fatigue)	- 0.10 [ 0.06, 0.14]	3.19
Dimopoulou 2022 (Muscles ache)	0.07 [ -0.01, 0.15]	2.81
Dimopoulou 2022 (Joint pain)	0.12 [ 0.02, 0.22]	2.55
Dimopoulou 2022 (Headache)	0.17 [ 0.05, 0.28]	2.35
Dimopoulou 2022 (Fatigue)	0.14 [ 0.04, 0.25]	2.44
Heterogeneity: $\tau^2 = 0.01$ , $I^2 = 91.27\%$ , $H^2 = 11.46$	0.12 [ 0.09, 0.16]	
Test of $\theta_i = \theta_j$ : Q(24) = 179.22, p = 0.00	·	
Severe neurodisabilities		
King 2022 (Fever)	0.14 [ -0.01, 0.28]	1.98
King 2022 (Feeling unwell)	0.14 [ -0.01, 0.28]	1.98
King 2022 (Fatigue)	0.27 [ 0.09, 0.46]	1.54
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.00\%$ , $H^2 = 1.00$	0.17 [ 0.08, 0.26]	
Test of $\theta_i = \theta_j$ : Q(2) = 1.59, p = 0.45	•	
Down syndrome		
Valentini 2022 (Fever)	0.10 [ 0.01, 0.19]	2.61
Valentini 2022 (Muscles ache)		3.14
Valentini 2022 (Headache)		3.14
Valentini 2022 (Fatigue)	0.05 [ -0.02, 0.12]	2.93
Heterogeneity: $\tau^2 = 0.00$ , $l^2 = 0.07\%$ , $H^2 = 1.00$	0.04 [ 0.01, 0.07]	
Test of $\theta_i = \theta_i$ : Q(3) = 2.38, p = 0.50	▼	
Type 1 diabetes mellitus	_	
Piccini 2022 (Fever)	0.26 [ 0.12, 0.39]	2.05
Piccini 2022 (Muscles ache)	0.13 [ 0.02, 0.23]	2.46
Piccini 2022 (Headache)	0.31 [ 0.16, 0.45]	1.96
Piccini 2022 (Weakness)	0.44 [ 0.28, 0.59]	1.84
Heterogeneity: $\tau^2 = 0.01$ , $I^2 = 72.30\%$ , $H^2 = 3.61$	0.27 [ 0.15, 0.40]	
Test of $\theta_i = \theta_j$ : Q(3) = 11.30, p = 0.01	<b>-</b>	
Solid tumour		
Riviere 2021 (Fever)	0.31 [ 0.06, 0.56]	1.06
Riviere 2021 (Vomiting)	0.08 [ -0.07, 0.22]	1.96
Riviere 2021 (Fatigue)	0.38 [ 0.12, 0.65]	0.99
Heterogeneity: $\tau^2 = 0.02$ , $I^2 = 60.23\%$ , $H^2 = 2.51$	0.23 [ 0.03, 0.43]	
Test of $\theta_i = \theta_j$ : Q(2) = 5.24, p = 0.07	▼	
Overall	0.13 [ 0.10, 0.17]	
Heterogeneity: τ² = 0.01, l² = 90.27%, H² = 10.28	•	
Test of $\theta_i = \theta_j$ : Q(38) = 244.42, p = 0.00		
Test of group differences: $Q_b(4) = 29.31$ , p = 0.00		
	0 .2 .4 .6	

- Figure 3: Forest plot of the proportion of any systemic reaction among immune-compromised adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.

Α		Effect Size	Weight
Study		with 95% CI	(%)
Rheumatic diseases			
Akgun 2022 (Local reactions)		0.61 [ 0.46, 0.76]	12.92
Akgun 2022 (Systemic reactions)		0.41 [ 0.26, 0.57]	12.87
Heterogeneity: $\tau^2 = 0.01$ , $I^2 = 68.84\%$ , $H^2 = 3.21$		0.51 [ 0.32, 0.70]	
Test of $\theta_i = \theta_j$ : Q(1) = 3.21, p = 0.07			
Down syndrome			
Valentini 2022 (Local reactions)		0.25 [ 0.12, 0.38]	13.41
Valentini 2022 (Systemic reactions)		0.12 [ 0.02, 0.23]	14.37
Heterogeneity: τ² = 0.00, l² = 52.50%, H² = 2.11		0.18 [ 0.06, 0.30]	
Test of $\theta_i = \theta_j$ : Q(1) = 2.11, p = 0.15			
Cystic fibrosis			
Michos 2022 (Local reactions)		0.24 [ 0.10, 0.39]	13.03
Michos 2022 (Systemic reactions)		0.12 [ 0.01, 0.23]	14.12
Heterogeneity: τ² = 0.00, l² = 40.02%, H² = 1.67	$\bullet$	0.17 [ 0.05, 0.29]	
Test of $\theta_i = \theta_j$ : Q(1) = 1.67, p = 0.20			
Solid tumour			
Riviere 2021 (Local reactions)		0.46 [ 0.19, 0.73]	9.00
Riviere 2021 (Systemic reactions)		0.23 [ 0.00, 0.46]	10.28
Heterogeneity: $\tau^2 = 0.01$ , $I^2 = 38.56\%$ , $H^2 = 1.63$		0.33 [ 0.11, 0.56]	
Test of $\theta_i = \theta_j$ : Q(1) = 1.63, p = 0.20			
Overall	-	0.30 [ 0.17, 0.42]	
Heterogeneity: τ² = 0.02, l² = 82.03%, H² = 5.56		-	
Test of $\theta_i = \theta_j$ : Q(7) = 39.96, p = 0.00			
Test of group differences: $Q_{p}(3) = 10.80$ , p = 0.01			
	0 .2 .4 .6 .	ר 8	
Random-effects REML model	· · · · · · · · ·	~	
L			

в Study		Effect Size with 95% Cl	Weight (%)
Rheumatic diseases			
Akgun 2022 (Local reactions)		0.61 [ 0.46, 0.76]	9.10
Akgun 2022 (Systemic reactions)		0.41 [ 0.26, 0.57]	9.08
Haslak 2021 (Local reactions)	<b>.</b>	0.09 [ 0.05, 0.13]	10.39
Dimopoulou 2022 (Local reactions)		0.74 [ 0.61, 0.87]	9.36
Dimopoulou 2022 (Systemic reactions)		0.19[ 0.07, 0.31]	9.57
Heterogeneity: $\tau^2 = 0.07$ , $I^2 = 96.18\%$ , $H^2 = 26.15$		0.40 [ 0.16, 0.65]	
Test of $\theta_i = \theta_j$ : Q(4) = 128.15, p = 0.00			
Down syndrome			
Valentini 2022 (Local reactions)		0.25 [ 0.12, 0.38]	9.34
Valentini 2022 (Systemic reactions)		0.15 [ 0.04, 0.26]	9.68
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 21.25\%$ , $H^2 = 1.27$	•	0.19 [ 0.10, 0.29]	
Test of $\theta_i = \theta_j$ : Q(1) = 1.27, p = 0.26			
Cystic fibrosis			
Michos 2022 (Local reactions)		0.27 [ 0.12, 0.42]	9.06
Michos 2022 (Systemic reactions)		0.27 [ 0.12, 0.42]	9.06
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.01\%$ , $H^2 = 1.00$	•	0.27 [ 0.17, 0.38]	
Test of $\theta_i = \theta_j$ : Q(1) = -0.00, p = 1.00			
Solid tumour			
Riviere 2021 (Local reactions)		0.15 [ -0.04, 0.35]	8.30
Riviere 2021 (Systemic reactions)	<b>_</b>	0.38 [ 0.12, 0.65]	7.08
Heterogeneity: $\tau^2 = 0.01$ , $I^2 = 47.03\%$ , $H^2 = 1.89$		0.25 [ 0.03, 0.47]	
Test of $\theta_i = \theta_j$ : Q(1) = 1.89, p = 0.17			
Overall	-	0.32 [ 0.19, 0.44]	
Heterogeneity: $\tau^2 = 0.04$ , $I^2 = 91.29\%$ , $H^2 = 11.48$			
Test of $\theta_i = \theta_j$ : Q(10) = 133.77, p = 0.00			
Test of group differences: $Q_b(3) = 3.03$ , p = 0.39			
	0.5	- 1	
Random-effects REML model			

Figure 4: Forest plot of the proportion of combined any local and any systemic reaction 560 561 among immune-compromised adolescents following receipt of the first (Panel 2A) and 562 second (Panel 2B) doses of BNT162b2 vaccine.

563

A Im Study	munocomprom Positive Ab	ized gro Total	up Control Positive Ab					Log Risk-Ratio with 95% Cl	Weight (%)
Bekenstein 2022 (Rheumatic disease)	36	37	22	22 —		_		0.01 [ -0.39, 0.36]	39.46
Michos 2022 (Cystic fibrosis)	32	33	63	66		_		0.01 [ -0.30, 0.31]	60.54
Overall								-0.00 [ -0.24, 0.24]	
Heterogeneity: τ <sup>2</sup> = 0.00, l <sup>2</sup> = 0.00%, H <sup>2</sup> =	= 1.00								
Test of $\theta_i = \theta_i$ : Q(1) = 0.01, p = 0.93									
Test of $\theta$ = 0: z = -0.00, p = 1.00									
				4	2	Ó	.2	.4	
Random-effects REML model									

Study	munocompromi Positive Ab	Total	Positive Al	ol group Total			Log Risk-Ratio with 95% Cl	Weigł (%)
Michos 2022 (Cystic fibrosis)	27	33	38	66			- 0.21 [ -0.17, 0.59]	42.02
Valentini 2022 (Down syndrome)	39	40	36	36			-0.01 [ -0.33, 0.31]	57.98
Overall						-	0.08 [ -0.16, 0.32]	
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.009$	%, Η <sup>2</sup> = 1.00							
Test of $\theta_i = \theta_j$ : Q(1) = 0.76, p = 0.38	3							
Test of $\theta$ = 0: z = 0.64, p = 0.52								
				5	0	.5	-	
Random-effects REML model								

- Figure 5: Forest plot of antibodies neutralization among immune-compromised vs
- healthy adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses
- of BNT162b2 vaccine.

### 

Α	Immuno	compromiz	ed group		Control g	roup			N	lean Diff.		Weight
στααγ	N	Mean	SD	Ν	Mean	SD			wi	th 95% CI		(%)
Down syndrome												
Valentini 2022 (28 days)	40	14.2903	7.6893	36	51.2767	71.0311			-36.99 [	-59.13,	-14.85]	26.16
Valentini 2022 (180 days)	40	1164.51	1153.39	36	2595.479	1273.927 -			-1430.97 [	-1976.65,	-885.29]	22.63
Valentini 2022 (21 days)	40	1100	153.786	36	953.3125	193.0193			146.69 [	68.59,	224.79]	26.08
Heterogeneity: τ <sup>2</sup> = 665984	.28, l² = 99	9.75%, H <sup>2</sup> =	397.22						-405.24 [	-1345.59,	535.12]	
Test of $\theta_i = \theta_j$ : Q(2) = 45.19	, p = 0.00											
Cystic fibrosis												
Michos 2022	33	222.45	1162.05	66	35.31	105.75			187.14 [	-94.10,	468.38]	25.12
Heterogeneity: $\tau^2 = 0.00$ , $I^2$	= .%, H <sup>2</sup> =							•	187.14 [	-94.10,	468.38]	
Test of $\theta_i = \theta_j$ : Q(0) = 0.00,	p = .											
Overall									-248.25 [	-954.51,	458.01]	
Heterogeneity: τ <sup>2</sup> = 496224	.13, l² = 99	9.53%, H <sup>2</sup> =	212.67									
Test of $\theta_i = \theta_j$ : Q(3) = 47.37	, p = 0.00											
Test of group differences: C	$Q_{\rm b}(1) = 1.40$	0, p = 0.24										
						-200	00 -1000	Ó	1000			
Random-effects REML mode	el											

В	Immunoc	ompromize	ed group		Control group				Mean Diff.			Weight	
Study	Ν	N Mean SD N Mean SD							with 95% CI			(%)	
Rheumatic disease													
Bekenstein 2022 (3 months)	37	93.07	52.46	22	149.15	22.04				-56.08 [	-79.18,	-32.98]	25.06
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .00$	%, H <sup>2</sup> = .								•	-56.08 [	-79.18,	-32.98]	
Test of $\theta_i = \theta_j$ : Q(0) = 0.00, p =	÷.												
Down syndrome													
Valentini 2022 (28 days)	40	107.26	76.893	36	164.8792	169.857			- 🗖 -	-57.62 [	-115.91,	0.68]	24.89
Valentini 2022 (180 days)	40	107.26	76.893	36	800	30.88				-692.74 [	-719.63,	-665.85]	25.05
Valentini 2022 (45 days)	40	143.55	84.58	36	143.55	84.93				0.00 [	-38.16,	38.16]	25.00
Heterogeneity: $\tau^2 = 147616.39$	), I <sup>2</sup> = 99.7	3%, H <sup>2</sup> = 3	74.90				_			<del>-250</del> .53 [	-686.01,	184.95]	
Test of $\theta_i = \theta_j$ : Q(2) = 1008.43,	, p = 0.00												
Overall							-			<del>2</del> 01.91 [	-524.28,	120.45]	
Heterogeneity: $\tau^2 = 107812.87$	, I <sup>2</sup> = 99.7	4%, H <sup>2</sup> = 3	91.12										
Test of $\theta_i = \theta_j$ : Q(3) = 1518.17,	p = 0.00												
Test of group differences: $Q_b(1)$	l) = 0.76, p	0 = 0.38											
						-8	00 -600	-400 -20	io o				
Random-effects REML model													

Figure 6: Forest plot of IgG (AU/ml) among immune-compromised vs healthy adolescents following receipt of the first (Panel 2A) and second (Panel 2B) doses of BNT162b2 vaccine.